ArticleClinical and experimental pediatrics2021
Consideration in treatment decisions for refractory Mycoplasma pneumoniae pneumonia.
Article in Clinical and experimental pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 14 citations in OpenAlex.
- Efficacy of Gamma Globulin Combined with Azithromycin Sequential Therapy in the Treatment of RMPP and Its Effect on Th1/Th2 Cytokine Levels.Computational and mathematical methods in medicine · 2022Trial
- Current Practice in the Diagnosis and Management ofJournal of Korean medical science · 2026Article
- Independent risk factors and predictive model for high hospitalization costs in children with Mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infection and drug resistance · 2026Review
- Screening of early predictive serum biomarkers and construction of a combined predictive model for refractoryFrontiers in pediatrics · 2026Article
- Effect of intravenous immunoglobulin combined with azithromycin sequential therapy on clinical outcomes and immune response in children withFrontiers in medicine · 2026Article
- The efficacy and adverse reactions of minocycline againstJournal of thoracic disease · 2025Article
- Improvement of IL-4, IL-6, IL-10, TNF-α and IFN-γ in children with mycoplasma pneumonia through the combination of video scenario-based breathing training and antibiotics.Sleep & breathing = Schlaf & Atmung · 2025Article
- Efficacy and safety of combined Linggui Bafa Tui Na and Fuxiong San herbal powder therapy in pediatric Mycoplasma pneumonia.American journal of translational research · 2025Article
- The relationship between IFN-γ, IL-10, IL-6 cytokines, and severity of the condition with serum zinc and Fe in children infected withOpen medicine (Warsaw, Poland) · 2024Article
- The analysis of risk factors for recurrent wheezing in infants and clinical intervention.Translational pediatrics · 2023Article
- Investigating the occurrence of autoimmune diseases among children and adolescents hospitalized forFrontiers in immunology · 2023Article
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- [Value of autotaxin in predicting refractoryZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- A prediction study of IL-18 and IFN-γ in glucocorticoid treatment response in infants and young children with severeTranslational pediatrics · 2022Article
- Association of children wheezing diseases with meteorological and environmental factors in Suzhou, China.Scientific reports · 2022Article
- Clinical Characteristics of Macrolide-RefractoryJournal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae (MP) is the most common cause of childhood bacterial pneumonia. Although macrolide is known to be effective as a first-line therapy, the proportion of macrolide resistance in MP pneumonia has strikingly increased during recent 2 decades in East Asia. This is challenging to physicians since they have to decide more often whether to use secondary treatment. Diagnostic methods to detect macrolide-resistance of MP are currently not available in Korean hospitals. Even in the diagnosis of MP infection, both serologic and molecular test have limitation: inability to differentiate current illness from carriage or asymptomatic infection. Combining these 2 diagnostic methods and excluding infection caused by other respiratory pathogens allow a more reliable diagnosis. This effort is even more demanding in recent years to keep children from unnecessary exposure to secondary antibiotics. Although several observational studies have reported that tetracycline and fluoroquinolone, which are considered in the treatment of refractory MP pneumonia, have efficacy of shortening the duration of fever and respiratory symptoms, those findings need to be proven by well-designed prospective studies. The use of tetracycline and fluoroquinolone in children is generally tolerable, as supported by many observational data. However, since concerns about side effects still remain, careful consideration about benefits and risks is needed to decide their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.